Pulmonary Vein Isolation
13
1
3
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 13 trials
100.0%
+13.5% vs benchmark
15%
2 trials in Phase 3/4
0%
0 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (13)
P-wave Duration and Local Potential as Predictors of AF Recurrence Following Pulmonary Vein Isolation
Impact of Atrial Fibrillation Ablation on Sleep Parameters.
'Understanding the Electrophysiological Substrate Underlying Persistent Atrial Fibrillation Study II (USURP AF- Study II)'
PulseSelect Based Pulmonary Vein Isolation and Ablation in Patients With Atrial Fibrillation
Empiric Pulsed Field Pulmonary Vein Isolation During Atrial Tachycardia Ablation in Adults With Congenital Heart Disease
Impact of Catheter Stability on the Outcomes With Very High Power Short Duration Ablation
CLOSE Versus High Density Mapping Guided Catheter Ablation of Paroxysmal Atrial Fibrillation
Left Atrial Posterior Wall Additional Isolation for Persistent Atrial Fibrillation Trial
Lesion Characteristics After Pulsed-Field Ablation in Patients With Atrial Fibrillation and a Left Common Ostium
Wide Area Circumferential Ablation With Contact Force Versus Cryoballoon Ablation
The Comparison Between the PVAM and CPVI for the Patients of PAF
Comparison of Pulmonary Vein Isolation Using SmartTouch® Catheter With or Without Real-time Contact Force Data
ADenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination: the ADVICE Trial